Mesenteric venous thrombosis

Mayo Clinic Proceedings

Volumn 88, Issue 3, 2013, Pages 285-294

  Singal, Ashwani K ^a   Kamath, Patrick S ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ATECEGATRAN METOXIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; DABIGATRAN; EDOXABAN; FONDAPARINUX; HEPARIN; JANUS KINASE 2; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; RIVAROXABAN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; XIMELAGATRAN;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ACUTE DISEASE; ALGORITHM; ANTICOAGULANT THERAPY; BLEEDING; CHRONIC DISEASE; CLINICAL FEATURE; COLLATERAL CIRCULATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG HALF LIFE; DRUG METABOLISM; ESOPHAGUS VARICES; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFERIOR MESENTERIC VEIN; INFLAMMATION; INTESTINE INFARCTION; LIVER CIRRHOSIS; MESENTERIC ARTERY OCCLUSION; MESENTERIC VEIN; MESENTERIC VEIN THROMBOSIS; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PATIENT CARE; PORTAL HYPERTENSION; PREVALENCE; SHORT BOWEL SYNDROME; STOMACH VARICES; SUPERIOR MESENTERIC VEIN; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 84876529063     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.01.012     Document Type: Conference Paper

References (47)

1. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001;345(23):1683-1688. (Pubitemid 33126825)
2. Rhee RY, Gloviczki P. Mesenteric venous thrombosis. Surg Clin North Am. 1997;77(2):327-338. (Pubitemid 27202818)
3. Brunaud L, Antunes L, Collinet-Adler S, et al. Acute mesenteric venous thrombosis: case for nonoperative management. J Vasc Surg. 2001;34(4):673-679. (Pubitemid 33664918)
4. Harnik IG, Brandt LJ. Mesenteric venous thrombosis. Vasc Med. 2010;15(5):407-418.
5. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95(10):1245-1251.
6. Kumar S, Kamath PS. Acute superior mesenteric venous thrombosis: one disease or two? Am J Gastroenterol. 2003;98(6):1299-1304. (Pubitemid 36741526)
7. Grisham A, Lohr J, Guenther JM, Engel AM. Deciphering mesenteric venous thrombosis: imaging and treatment. Vasc Endovasc Surg. 2005;39(6):473-479. (Pubitemid 41790138)
8. Alvi AR, Khan S, Niazi SK, Ghulam M, Bibi S. Acute mesenteric venous thrombosis: improved outcome with early diagnosis and prompt anticoagulation therapy. Int J Surg. 2009;7(3):210-213.
9. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200-205.
10. Abu-Daff S, Abu-Daff N, Al-Shahed M. Mesenteric venous thrombosis and factors associated with mortality: a statistical analysis with five-year follow-up. J Gastrointest Surg. 2009; 13(7):1245-1250.
11. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102(11):2464-2470. (Pubitemid 47631782)
12. Orr DW, Patel RK, Lea NC, et al. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic portosplenomesenteric venous thrombosis. Aliment Pharmacol Ther. 2010;31(12):1330-1336.
13. Zhang J, Duan ZQ, Song QB, Luo YW, Xin SJ, Zhang Q. Acute mesenteric venous thrombosis: a better outcome achieved through improved imaging techniques and a changed policy of clinical management. Eur J Vasc Endovasc Surg. 2004;28(3): 329-334. (Pubitemid 39069369)
14. Morasch MD, Ebaugh JL, Chiou AC, Matsumura JS, Pearce WH, Yao JS. Mesenteric venous thrombosis: a changing clinical entity. J Vasc Surg. 2001;34(4):680-684. (Pubitemid 33664919)
15. Cenedese A, Monneuse O, Gruner L, Tissot E, Mennesson N, Barth X. Initial management of extensive mesenteric venous thrombosis: retrospective study of nine cases. World J Surg. 2009;33(10):2203-2208.
16. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
17. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32(3):466-470.
18. Amarapurkar DN, Patel ND, Jatania J. Primary mesenteric venous thrombosis: a study from western India. Indian J Gastroenterol. 2007;26(3):113-117. (Pubitemid 47296198)
19. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia: American Gastrointestinal Association. Gastroenterology. 2000; 118(5):954-968. (Pubitemid 30243759)
20. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc Surg. 2010;23(1):4-8.
21. Acosta S, Alhadad A, Ekberg O. Findings in multi-detector row CT with portal phase enhancement in patients with mesenteric venous thrombosis. Emerg Radiol. 2009;16(6): 477-482.
22. Lee SS, Ha HK, Park SH, et al. Usefulness of computed tomography in differentiating transmural infarction from nontransmural ischemia of the small intestine in patients with acute mesenteric venous thrombosis. J Comput Assist Tomogr. 2008; 32(5):730-737.
23. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5(4):708-714. (Pubitemid 46563568)
24. Fiorini A, Chiusolo P, Rossi E, et al. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Am J Hematol. 2009;84(2):126-127.
25. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5(1):55-61. (Pubitemid 44921067)
26. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134(1):82-85.
27. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10): 4922-4929.
28. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44(6): 1528-1534. (Pubitemid 44953658)
29. Spivak JL. Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations; the phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 2010;152(5):300-306.
30. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008;49(3):388-397. (Pubitemid 351298324)
31. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842-3847.
32. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-2466. (Pubitemid 44903749)
33. Kanellopoulou T, Alexopoulou A, Theodossiades G, Koskinas J, Archimandritis AJ. Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis. 2010; 42(11-12):804-811.
34. Maan A, Padmanabhan R, Shaikh AY, Mansour M, Ruskin JN, Heist EK. Newer anticoagulants in cardiovascular disease: a systematic review of the literature. Cardiol Rev. 2012; 20(5):209-221.
35. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210-218.
36. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691-697. (Pubitemid 40559257)
37. Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16(5):651-661. (Pubitemid 40647208)
38. Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51(1):306.
39. Semiz-Oysu A, Keussen I, Cwikiel W. Interventional radiological management of prehepatic obstruction of [corrected] the splanchnic venous system [published correction appears in Cardiovasc Intervent Radiol. 2008;31(1):232].
40. Cardiovasc Intervent Radiol. 2007;30(4):688-695.
41. Dentali F, Ageno W, Witt D, et al; WARPED consortium. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost. 2009;102(3):501-504.
42. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410-2415.
43. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. (Pubitemid 46120195)
44. de Franchis R; Baveno V faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762-768.
45. Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56(7):1001-1008. (Pubitemid 46999087)
46. Madsen MS, Petersen TH, Sommer H. Segmental portal hypertension. Ann Surg. 1986;204(1):72-77. (Pubitemid 16053828)
47. Orr DW, Harrison PM, Devlin J, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2007; 5(1):80-86. (Pubitemid 46096827)